Table 2.
Baseline antiretroviral resistance
| Overall (n = 139) | First diagnosed in Canada (n = 60) | First diagnosed before arrival to Canada (n = 79) | |
|---|---|---|---|
| HIV Genotype available | 80 (58%) | 57 (95%) | 23 (29%) |
| Baseline antiretroviral resistancea | |||
| No | 60 (75%) | 45 (79%) | 15 (65%) |
| Yes | 20 (25%) | 12 (21%) | 8 (35%) |
| NRTI resistance | 6 (8%) | 2 (4%) | 4 (17%) |
| NNRTI resistance | 17 (21%) | 12 (21%) | 5 (22%) |
| PI resistance | 0 (0%) | 0 (0%) | 0 (0%) |
| II resistance | 1 (1%) | 1 (2%) | 0 (0%) |
| Multidrug resistance | 3 (4%) | 2 (4%) | 1 (4%) |
| M184 V/I mutation | 3 (4%) | 2 (4%) | 1 (4%) |
| K103 N/S mutation | 11 (14%) | 7 (12%) | 4 (17%) |
| K65R mutation | 0 (0%) | 0 (0%) | 0 (0%) |
| TAMs | 1 (1%) | 1 (2%) | 0 (0%) |
aThe denominator for these proportions is the number of patients with available genotypic data (i.e. 80 for overall, 57 for first diagnosed in Canada, and 23 for first diagnosed before arrival to Canada)
II integrase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, PI protease inhibitor, TAMs Thymidine analogue mutations